| | | I think it's important that we understand how important this ASCO presentation is. This year, around 266,000 women in the US will be diagnosed with invasive breast cancer. Only 15% of those will have TNBC, but two thirds of breast cancer is hormone receptor positive. Even if you assume that SG will be used only in cases failing standard therapy, use of SG in this patient population would dramatically increase the potential patient population. And that's just in the U.S; around the world, over 1.7 million women will be diagnosed with breast cancer every year, meaning over 1 million women with hormone receptor positive invasive breast cancer will be potential patients for SG.
Moreover, the fact that this was given an oral presentation spot rather than a simple poster presentation means the ASCO organizers feel that it is a significant piece of research, and needs a larger audience.
If the data is good, and presumably it is based on Immunomedics advertising it with an investor presentation at ASCO, then the company could see large scale off label use after it gets TNBC accelerated approval, and while confirmatory studies are being done.
Basically, "silly" valuation of the company may be closer than previously thought.
Now bring on urothelial breakthrough status! |
|
